04:27:51 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-29 Kvartalsrapport 2024-Q2
2024-05-16 X-dag ordinarie utdelning BRAINP 0.00 DKK
2024-05-15 Årsstämma 2024
2024-05-07 Bokslutskommuniké 2023
2023-10-11 Extra Bolagsstämma 2023
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-30 X-dag ordinarie utdelning BRAINP 0.00 DKK
2023-05-26 Årsstämma 2023
2023-04-28 Bokslutskommuniké 2022
2022-09-29 Kvartalsrapport 2022-Q2
2022-09-02 Extra Bolagsstämma 2022
2022-05-19 X-dag ordinarie utdelning BRAINP 0.00 DKK
2022-05-18 Årsstämma 2022
2022-04-29 Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaFirst North Denmark
SektorHälsovård
IndustriVård & Omsorg
Brain+ är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling för behandling av demens och alzheimers. Produktportföljen inkluderar exempelvis kognitiv stimuleringsterapi. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs med störst närvaro inom Europa. Brain+ har sitt huvudkontor i Köpenhamn.
2024-05-31 13:59:28

Copenhagen, Denmark, 31 May 2024 - Brain+ A/S (Nasdaq First North: BRAINP)

The Board of Directors of Brain+ A/S ("Brain+" or the "Company") decided on 7 May 2024, with following approval from the Annual General Meeting held on 22 May 2024, to carry out a rights issue of units (the "Rights Issue"). The subscription period in the Rights Issue commences on 11 June 2024 and lasts until and including 24 June 2024. Brain+ has today published an investment brochure with information about the Company, its business, products and strategy, and about the Rights Issue. The investment brochure is attached to this announcement and is also available on the websites of Brain+ and Sedermera Corporate Finance AB. For complete information about the Rights Issue, please see Brain+' company announcement from 7 May 2024 (https://websolutions.ne.cision.com/releasedetail.html?releaseIdentifier=790256354D5B017F).

Investment brochure

In order to provide existing shareholders of Brain+ as well as other investors and stakeholders to the Company with information prior to the Rights Issue, an investment brochure has been established. The investment brochure provides information about the Company, its business, products and strategy, and about the Rights Issue. It is attached to this announcement and is also available on the websites of Brain+ and its financial advisor Sedermera Corporate Finance AB

For complete information about the Rights Issue please see Brain+' company announcement from 7 May 2024 (https://websolutions.ne.cision.com/releasedetail.html?releaseIdentifier=790256354D5B017F).

Summary of the Rights Issue
  • All existing shareholders in Brain+ will receive one (1) unit right for each share held on the record date, the 10 June 2024. For nine (9) unit rights the holder will be entitled to subscribe for one (1) unit.
  • One (1) unit consists of eleven (11) new shares in Brain+ and nine (9) warrants of series TO 4. So, subscription for one unit means subscription for eleven (11) new Brain+ shares and nine (9) warrants of series TO 4.
  • The subscription price is DKK 0.88 per unit, corresponding to a subscription price of DKK 0.08 per share. Warrants are issued free of charge.
  • The subscription period commences on 11 June 2024 at 9:00 a.m. CEST (Central European Summer Time = local Danish and Swedish time) and will close on 24 June 2024 CEST.
  • The Rights Issue comprises a maximum of 10,161,031 units, corresponding to a total of 111,771,341 new shares and 91,449,279 warrants of series TO 4. If fully subscribed, Brain+ will receive approximately DKK 8.94 million in gross proceeds before issue related costs of approximately DKK 1.85 million. The warrants of series TO 4 can, if the Rights Issue is fully subscribed, and all warrants of series TO 4 subsequently are exercised for subscription at the highest exercise price of DKK 0.10, provide the Company with up to approximately DKK 9.14 million in additional gross proceeds.

Timeline for the Rights Issue

Last day of trading in the share 6 June
incl. unit rights
First day of trading in the share 7 June
excl. unit rights
First day of trading in unit 7 June
rights
Record date for obtaining unit 10 June
rights
Subscription period 11 June - 24 June
Last day of trading in unit 20 June
rights
Estimated date for publication of 27 June
outcome
Estimated date for first day of 11 July
trading in new shares and
warrants

Questions related to the Rights Issue
In case of any question about Brain+, the Rights Issue or the financial instruments, you are welcome to reach out to either Brain+ CEO Kim Baden-Kristensen, Brain+ CFO Hanne Vissing Leth, Brain+ financial adviser Sedermera Corporate Finance or the issuing agent Nordic Issuing using the contact details at the bottom of this company announcement.

Advisors
In connection with the Rights Issue, Sedermera Corporate Finance AB act as financial advisors to Brain+. Markets & Corporate Law Nordic AB act as legal advisor. Nordic Issuing AB it the issuing agent and the settlement agent.

For more information about the Rights Issue, please contact:

Sedermera Corporate Finance AB
Phone: +46 (0) 40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se

For more information about technicalities and the financial instruments, please contact:

Nordic Issuing AB
Phone: +46 (0) 40 632 00 20
E-mail: info@nordic-issuing.se
www.nordic-issuing.se
 

For more information about Brain+, please contact:

Kim Baden-Kristensen, CEO
Phone: +45 31393317
E-mail: kim@brain-plus.com

www.brain-plus.com

Certified Adviser

Keswick Global AG

Phone: +43 1 740 408 045

E-mail: info@keswickglobal.com